drugset / Trial / NCT01871974

Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder

NCT01871974

Phase 1 Completed 16 enrolled Astellas Pharma Inc
Non-randomizedSingle-groupOpen-labelOther

Summary

The objective of the study was to evaluate the safety and plasma concentration changes of quetiapine after multiple oral administration of FK949E (extended-release formulation of quetiapine) in patients with major depressive disorder (MDD).

Timeline

Start
2009-05
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule Oral